Practice Guidelines for the Treatment of Candidiasis
The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
Abstract
Infections due to Candida species are the most common of the fungal infections. Candida species produce a broad range of infections, ranging from non-life-threatening mucocutaneous illnesses to invasive process that may involve virtually any organ. Such a broad range of infections requires an equally broad range of diagnostic and therapeutic strategies. This document summarizes current knowledge about treatment of multiple forms of candidiasis and is the guideline of the Infectious Diseases Society of America (IDSA) for the treatment of candidiasis. Throughout this document, treatment recommendations are scored according to the standard scoring scheme used in other IDSA guidelines to illustrate the strength of the underlying data. The document covers 4 major topical areas. The role of the microbiology laboratory. To a greater extent than for other fungi, treatment of candidiasis can now be guided by in vitro susceptibility testing. The guidelines review the available information supporting current testing procedures and interpretive breakpoints and place these data into clinical context. Susceptibility testing is most helpful in dealing with infection due to non-albicans species of Candida. In this setting, especially if the patient has been treated previously with an azole antifungal agent, the possibility of microbiological resistance must be considered. Treatment of invasive candidiasis. In addition to acute hematogenous candidiasis, the guidelines review strategies for treatment of 15 other forms of invasive candidiasis. Extensive data from randomized trials are really available only for therapy of acute hematogenous candidiasis in the nonneutropenic adult. Choice of therapy for other forms of candidiasis is based on case series and anecdotal reports. In general, both amphotericin B and the azoles have a role to play in treatment. Choice of therapy is guided by weighing the greater activity of amphotericin B for some non-albicans species (e.g., Candida krusei) against the lesser toxicity and ease of administration of the azole antifungal agents. Flucytosine has activity against many isolates of Candida but is not often used. Treatment of mucocutaneous candidiasis. Therapy for mucosal infections is dominated by the azole antifungal agents. These drugs may be used topically or systemically and have been proven safe and efficacious. A significant problem with mucosal disease is the propensity for a small proportion of patients to suffer repeated relapses. In some situations, the explanation for such a relapse is obvious (e.g., relapsing oropharyngeal candidiasis in an individual with advanced and uncontrolled HIV infection), but in other patients the cause is cryptic (e.g., relapsing vaginitis in a healthy woman). Rational strategies for these situations are discussed in the guidelines and must consider the possibility of induction of resistance over time. Prevention of invasive candidiasis. Prophylactic strategies are useful if the risk of a target disease is sharply elevated in a readily identified group of patients. Selected patient groups undergoing therapy that produces prolonged neutropenia (e.g., some bone-marrow transplant recipients) or who receive a solid-organ transplant (e.g., some liver transplant recipients) have a sufficient risk of invasive candidiasis to warrant prophylaxis. Relationship between epidemiology of candidal infections and therapy. Although Candida albicans remains the most common pathogen in oropharyngeal and cutaneous candidiasis, non-albicans species of Candida are increasingly frequent problems in both invasive candidiasis [1] and vaginal candidiasis [2]. This is particularly problematic in patients with acutely life-threatening invasive candidal infections. Although the susceptibility of Candida to the currently available antifungal agents can be predicted if the species of the infecting isolate is known (table 1) [1, 3–13], individual isolates do not necessarily follow the general pattern. For example, C. albicans is usually susceptible to all major agents. However, azole resistance for this species is now well described among HIV-infected individuals with relapsing oropharyngeal candidiasis and is also reported sporadically in critically ill adults with invasive candidiasis [14]. For this reason, susceptibility testing for azole resistance is increasingly important in the management of candidiasis in patients. On the other hand, most Candida isolates appear to remain susceptible to amphotericin B, although recent data suggest that isolates of Candida glabrata and C. krusei may require maximal doses of amphotericin B (see below). General patterns of susceptibility of Candida species. Susceptibility testing and drug dosing. Intensive efforts to develop standardized, reproducible, and clinically relevant susceptibility testing methods for the fungi have resulted in the of the for susceptibility testing of interpretive breakpoints this are available for testing the susceptib
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The distribution of Candida species plays a key role for establishing efficient management strategies [23, 24].”
From Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000 (2004) · cites this paper as [23]
In the citing paper
“Finally, C. lusitaniae, C. guilliermondii, C. glabrata, and C. krusei have a generally lower susceptibility to polyenes [36,37].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [37]
In the citing paper
“In this regard, higher than usual doses of amphotericin B have been recommended by the Infectious Diseases Society of America for treating candidemia caused by C. glabrata and C. krusei [125].”
From Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents (2013) · cites this paper as [125]
In the citing paper
“Although C. glabrata is frequently considered to be susceptible to amphotericin B, it has a clear tendency to have higher minimum inhibitory concentration (MIC) values to polyenes than C. albicans [76,114].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [114]
Citations
Cites
The American Journal of Gastroenterology
(2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.80003397.x · Cited by 2,196
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Self-citationGoodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,174
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039 · cited 1×
“Two recent large randomized studies [47, 48] and 2 recent large observational studies [49, 50] have demonstrated that fluconazole at 400 mg/d and amphotericin B at 0.”
BackgroundSelf-citationPizzo, P. A., Robichaud, K. J., Gill, F. A., & Witebsky, F. G. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90594-0 · Cited by 859
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855 · cited 5×
“Shown are the breakpoints proposed for use with the reference broth susceptibility testing method [3] for Candida [16].”
BackgroundMethodInfluentialSelf-citationHospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831 · cited 1×
“Candida bloodstream infections are frequently associated with clinical evidence of the sepsis syndrome and high associated attributable mortality [46].”
BackgroundSlavin, M. A., Osborne, B., Adams, R., Levenstein, M. J., Schoch, H. G., Feldman, A. R., Meyers, J. D., & Bowden, R. A. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1545 · Cited by 820
Candida Colonization and Subsequent Infections in Critically III Surgical Patients
Pittet, D., Monod, M., Suter, P. M., Frenk, E., & Auckenthaler, R. (1994) · Annals of Surgery · doi:10.1097/00000658-199412000-00008 · Cited by 798 · cited 1×
“If therapy is given, its use should be limited to patients with (a) Candida colonization (preferably at multiple sites [58]), (b) multiple other risk factors, and (c) absence of any other uncorrected causes of fever (CIII).”
BackgroundVulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations
Sobel, J. D., Faro, S., Force, R. W., Foxman, B., Ledger, W. J., Nyirjesy, P. R., Reed, B. D., & Summers, P. R. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)80001-x · Cited by 694
Self-citationCandidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679
1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever
Hughes, W. T., Armstrong, D., Bodey, G. P., Brown, A. E., Edwards, J. E., Feld, R., Pizzo, P., Rolston, K. V. I., Shenep, J. L., & Young, L. S. (1997) · Clinical Infectious Diseases · doi:10.1086/513764 · Cited by 672
Self-citationGrant, S. M., & Clissold, S. P. (1990) · Drugs · doi:10.2165/00003495-199039060-00006 · Cited by 661
Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A., Bow, E., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 629
Self-citationSobel, J. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712253372607 · Cited by 449
Self-citationPfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00192-2 · Cited by 424
Edwards, Jr., Bodey, G. P., Bowden, R. A., Buchner, T., de Pauw, B. E., Filler, S. G., Ghannoum, M. A., Glauser, M., Herbrecht, R., Kauffman, C. A., et al. (1997) · Clinical Infectious Diseases · doi:10.1086/514504 · Cited by 418
Self-citationFluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients
Eggimann, P., Francioli, P., Bille, J., Schneider, R., Wu, M.-M., Chapuis, G., Chiolero, R., Pannatier, A., Schilling, J., Geroulanos, S., et al. (1999) · Critical Care Medicine · doi:10.1097/00003246-199906000-00019 · Cited by 414
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Self-citationHepatic Candidiasis in Cancer Patients: The Evolving Picture of the Syndrome
THALER, M., PASTAKIA, B., SHAWKER, T. H., O'LEARY, T., & PIZZO, P. A. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-1-88 · Cited by 395
Empiric antifungal therapy in febrile granulocytopenic patients
(1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90441-5 · Cited by 378
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Risk Factors for Hospital-Acquired Candidemia: A Matched Case-Control Study
Wey, S. B. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390100145030 · Cited by 369 · cited 1×
“Colonization by Candida of multiple nonsterile sites, prolonged use of antibacterial antibiotics, central venous catheters, hyperalimentation, surgery (especially surgery that transects the gut wall), and prolonged ICU stay have all been linked to increased risk of invasive candidiasis [58–60].”
BackgroundNguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363 · cited 3×
“The evidence for this recommendation is strongest in the nonneutropenic patient population [50, 55].”
BackgroundCandiduria: A Randomized, Double-Blind Study of Treatment with Fluconazole and Placebo
Sobel, J. D., Kauffman, C. A., McKinsey, D., Zervos, M., Vazquez, J. A., Karchmer, A. W., Lee, J., Thomas, C., Panzer, H., Dismukes, W. E., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313580 · Cited by 343 · cited 2×
“In candiduric individuals, Foley catheter change alone rarely results in elimination of candiduria (!20%); however, discontinuation of the catheter alone may result in eradication of candiduria in almost 40% of patients [76] (BIII).”
BackgroundSelf-citationKOSSOFF, E. H., BUESCHER, E. S., & KARLOWICZ, M. G. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199806000-00014 · Cited by 330
Sangeorzan, J. A., Bradley, S. F., He, X., Zarins, L. T., Ridenour, G. L., Tiballi, R. N., & Kauffman, C. A. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90300-x · Cited by 322
Powderly, W. G., Finkelstein, D. M., Feinberg, J., Frame, P., He, W., van der Horst, C., Koletar, S. L., Eyster, M. E., Carey, J., Waskin, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503163321102 · Cited by 318 · cited 8×
“Chronic suppressive therapy with fluconazole is effective in the prevention of oropharyngeal candidiasis in both AIDS [18, 137] and cancer patients [138].”
BackgroundInfluentialRisk Factors For Invasive Fungal Infections Complicating Orthotopic Liver Transplantation
Collins, L. A., Samore, M. H., Roberts, M. S., Luzzati, R., Jenkins, R. L., David Lewis, W., & Karchmer, A. W. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/170.3.644 · Cited by 311
EDWARDS, J. E., FOOS, R. Y., MONTGOMERIE, J. Z., & GUZE, L. B. (1974) · Medicine · doi:10.1097/00005792-197401000-00002 · Cited by 304
Self-citationRex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W., & Webb, C. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.40 · Cited by 301
Self-citationPredictors of Adverse Outcome in Cancer Patients with Candidemia
Anaissie, E. J., Rex, J. H., Uzun, Ö., & Vartivarian, S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00030-8 · Cited by 295
Self-citationEL-EBIARY, M., TORRES, A., FÁBREGAS, N., de la BELLACASA, J. P., GONZÁLEZ, J., RAMIREZ, J., del BAÑO, D., HERNÁNDEZ, C., & JIMÉNEZ de ANTA, M. T. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.2.9612023 · Cited by 271
Empirical antifungal therapy in febrile granulocytopenic patients
Meunier, F. (1989) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · Cited by 268
Introduction to Antifungal Drugs
Dismukes, W. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313748 · Cited by 262
Self-citationIntravascular Catheter Exchange and Duration of Candidemia
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., Serody, J., Edwards, J. E., Washburn, R. G., NIAID Mycoses Study Group, & Candidemia Study Group (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.4.994 · Cited by 252
Self-citationWebb, B. C., Thomas, C. J., Willcox, M. D. P., Harty, D. W. S., & Knox, K. W. (1998) · Australian Dental Journal · doi:10.1111/j.1834-7819.1998.tb00152.x · Cited by 251
Menichetti, F., Del Favero, A., Martino, P., Bucaneve, G., Micozzi, A., Girmenia, C., Barbabietola, G., Pagano, L., Leoni, P., Specchia, G., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/515129 · Cited by 244
CLINICAL SIGNIFICANCE OF CANDIDA ISOLATED FROM PERITONEUM IN SURGICAL PATIENTS
Calandra, T., Schneider, R., Bille, J., Mosimann, F., & Francioli, P. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92043-6 · Cited by 239
Francis, P., & Walsh, T. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.6.1003 · Cited by 232
Self-citationPhillips, P., Shafran, S., Garber, G., Rotstein, C., Smaill, F., Fong, I., Salit, I., Miller, M., Williams, K., Conly, J. M., et al. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01726360 · Cited by 221
Anaissie, E., Bodey, G. P., Kantarjian, H., David, C., Barnett, K., Bow, E., Defelice, R., Downs, N., File, T., Karam, G., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90006-j · Cited by 220
Nguyen, M. H., Clancy, C. J., Yu, V. L., Yu, Y. C., Morris, A. J., Snydman, D. R., Sutton, D. A., & Rinaldi, M. G. (1998) · The Journal of Infectious Diseases · doi:10.1086/514193 · Cited by 219 · cited 3×
“Data for amphotericin B also include results of studies in which modifications of the reference method have been used in enhanced detection of amphotericin B–resistant isolates [4, 8, 9].”
BackgroundMethodResultRecurrent Vulvovaginal Candidiasis
Sobel, J. D. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612043152305 · Cited by 217
Self-citationHunter, R. C. (1971) · PubMed · Cited by 215
Emergence of Candida parapsilosis as the Predominant Species Causing Candidemia in Children
Levy, I., Rubin, L. G., Vasishtha, S., Tucci, V., & Sood, S. K. (1998) · Clinical Infectious Diseases · doi:10.1086/520277 · Cited by 210
Wanger, A., Mills, K., Nelson, P. W., & Rex, J. H. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2520 · Cited by 202
Self-citationCOMPARISON OF FLUCONAZOLE AND KETOCONAZOLE FOR OROPHARYNGEAL CANDIDIASIS IN AIDS
De Wit, S., Goossens, H., Weerts, D., & Clumeck, N. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92572-5 · Cited by 199
Detection of amphotericin B-resistant Candida isolates in a broth-based system
Rex, J. H., Cooper, C. R., Merz, W. G., Galgiani, J. N., & Anaissie, E. J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.4.906 · Cited by 198
Self-citationThe role of Candida in intraperitoneal infections.
Solomkin, J. S., Flohr, A. B., Quie, P. G., & Simmons, R. L. (1980) · PubMed · Cited by 195
Hepatosplenic candidiasis: Successful treatment with fluconazole
Kauffman, C. A., Bradley, S. F., Ross, S. C., & Weber, D. R. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90005-i · Cited by 195
Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes
Goldie, S. J., Kiernan-Troidle, L., Torres, C., Gorban-Brennan, N., Dunne, D., Kliger, A. S., & Finkelstein, F. O. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90135-3 · Cited by 189
Bonacini, M. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.151.8.1567 · Cited by 189
Baley, J. E., Meyers, C., Kliegman, R. M., Jacobs, M. R., & Blumer, J. L. (1990) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)82674-5 · Cited by 184 · cited 1×
“Because clearance of flucytosine is directly proportional to glomerular filtration rate, very-low– birth weight infants may accumulate high plasma concentrations because of immature renal function [33].”
BackgroundTollemar, J., Höckerstedt, K., Ericzon, B.-G., Jalanko, H., & Ringdén, O. (1995) · Transplantation · doi:10.1097/00007890-199501150-00009 · Cited by 179
HADLEY, S., SAMORE, M. H., LEWIS, W. D., JENKINS, R. L., KARCHMER, A. W., & HAMMER, S. M. (1995) · Transplantation · doi:10.1097/00007890-199503000-00009 · Cited by 176
Treatment of Torulopsis glabrata Vaginitis: Retrospective Review of Boric Acid Therapy
Sobel, J. D., & Chaim, W. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.649 · Cited by 160
Self-citationCombined Therapy with Amphotericin B and 5-Fluorocytosine for Candida Meningitis
Smego, R. A., Perfect, J. R., & Durack, D. T. (1984) · Clinical Infectious Diseases · doi:10.1093/clinids/6.6.791 · Cited by 158
Benedetti, E., Gruessner, A. C., Troppmann, C., Papalois, B. E., Sutherland, D. E. R., Dunn, D. L., & Gruessner, R. W. G. (1996) · PubMed · Cited by 154
Eisenberg, E. S., Leviton, I., & Soeiro, R. (1986) · Clinical Infectious Diseases · doi:10.1093/clinids/8.3.309 · Cited by 152
Importance of Candida species other than Candida albicans as opportunistic pathogens.
Coleman, D. C., Rinaldi, M. G., Haynes, K., Rex, J. H., Summerbell, R. C., Anaissie, E. J., Li, A., & Sullivan, D. J. (1998) · PubMed · Cited by 149
Self-citationHorsburgh, C. R., & Kirkpatrick, C. H. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90511-9 · Cited by 149
Pulmonary disease caused by Candida species
Masur, H., Rosen, P. P., & Armstrong, D. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90546-0 · Cited by 146
Primary Candida pneumonia. Experience at a large cancer center and review of the literature.
Haron, E., Vartivarian, S. E., Anaissie, E. A., Dekmezian, R. H., & Bodey, G. P. (1993) · PubMed · Cited by 145
Marr, K. A., White, T. C., van Burik, J. H., & Bowden, R. A. (1997) · Clinical Infectious Diseases · doi:10.1086/515553 · Cited by 145
Primary Candida Pneumonia: Experience at a Large Cancer Center and Review of the Literature
Haron, E., Vartivarian, S., Anaissie, E., Dekmezian, R., & Bodey, G. P. (1993) · Medicine · doi:10.1097/00005792-199305000-00001 · Cited by 144 · cited 1×
“Observational reports and case series have shown that proven Candida pneumonia is associated with high mortality in patients with malignancies [82].”
Repeated-Dose Pharmacokinetics of an Oral Solution of Itraconazole in Infants and Children
de Repentigny, L., Ratelle, J., Leclerc, J.-M., Cornu, G., Sokal, E. M., Jacqmin, P., & de Beule, K. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.404 · Cited by 142
Pharmacokinetics of fluconazole in pediatric patients
Brammer, K. W., & Coates, P. E. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01974613 · Cited by 139
Liposomal amphotericin B treatment for neonatal fungal infections
SCARCELLA, A., PASQUARIELLO, M. B., GIUGLIANO, B., VENDEMMIA, M., & DE LUCIA, A. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199802000-00013 · Cited by 135 · cited 1×
“Liposomal amphotericin B was used successfully in 5 of 6 cases of Candida meningitis in newborn infants [117].”
MethodCandidemia from a Urinary Tract Source: Microbiological Aspects and Clinical Significance
Ang, B. S. P., Telenti, A., King, B., Steckelberg, J. M., & Wilson, W. R. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.662 · Cited by 132
Laine, L., Dretler, R. H., Conteas, C. N., Tuazon, C., Koster, F. M., Sattler, F., Squires, K., & Islam, M. Z. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-8-655 · Cited by 131
Bayer, A. S., Blumenkrantz, M. J., Montgomerie, J. Z., Galpin, J. E., Coburn, J. W., & Guze, L. B. (1976) · The American Journal of Medicine · doi:10.1016/0002-9343(76)90407-1 · Cited by 129
Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life
Saxén, H., Hoppu, K., & Pohjavuori, M. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.147 · Cited by 127 · cited 1×
“In particular, the pharmacology of fluconazole varies with neonatal age, making rational dosing somewhat difficult [31, 35, 36].”
BackgroundCartledge, J. D., Midgely, J., & Gazzard, B. (1997) · Journal of Clinical Pathology · doi:10.1136/jcp.50.6.477 · Cited by 124
Microwave disinfection of denture base materials colonized with Candida albicans
Dixon, D. L., Breeding, L. C., & Faler, T. A. (1999) · Journal of Prosthetic Dentistry · doi:10.1016/s0022-3913(99)70250-7 · Cited by 123
Invasive neonatal candidiasis: comparison of albicans and parapsilosis infection
FAIX, R. G. (1992) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199202000-00006 · Cited by 122 · cited 1×
“However, in premature or low–birth weight neonates or infants with prolonged rupture of membranes, the cutaneous process may become invasive and thus produce acute disseminated candidiasis [73].”
BackgroundRyder, N. S., Wagner, S., & Leitner, I. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1057 · Cited by 120
Safety and pharmacokinetics of fluconazole in children with neoplastic diseases
Lee, J. W., Seibel, N. L., Amantea, M., Whitcomb, P., Pizzo, P. A., & Walsh, T. J. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)81975-4 · Cited by 120
Bowden, R. A., Cays, M., Gooley, T., Mamelok, R. D., & van Burik, J.-A. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/173.5.1208 · Cited by 117
Philpott-Howard, J. N., Wade, J. J., Mufti, G. J., Brammer, K. W., & Ehniniger, G. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/31.6.973 · Cited by 114
Jacobs, L. G., Skidmore, E. A., Freeman, K., Lipschultz, D., & Fox, N. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.1.30 · Cited by 113
Meningitis Caused by Candida Species: An Emerging Problem in Neurosurgical Patients
Nguyen, M. H., & Yu, V. L. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.2.323 · Cited by 113
Surgical and long-term antifungal therapy for fungal prosthetic valve endocarditis
Muehrcke, D. D., Lytle, B. W., & Cosgrove, D. M. (1995) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00469-2 · Cited by 110 · cited 1×
“Removal of infected valves, resection of infected peripheral veins, and debridement of infected pericardial tissue are almost always required for successful therapy [106, 107].”
BackgroundWalsh, T. J., Whitcomb, P., Piscitelli, S., Figg, W. D., Hill, S., Chanock, S. J., Jarosinski, P., Gupta, R., & Pizzo, P. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1944 · Cited by 109
Self-citationBriscoe, D. M., Yeung, A. C., Schoen, E. L., Allred, E. N., Stavrakis, G., Ganz, P., Cotran, R. S., & Pober, J. S. (1995) · Transplantation · doi:10.1097/00007890-199501000-00009 · Cited by 108
Randomized Trial of Itraconazole Oral Solution for Oropharyngeal Candidiasis in HIV/AIDS Patients
Graybill, J. R., Vázquez, J. A., Darouiche, R. O., Morhart, R. E., Greenspan, D., Tuazon, C. U., Wheat, L. J., CAREY, J. J., Leviton, I. M., Hewitt, R. G., et al. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00307-0 · Cited by 108
Wilcox, C. M., Darouiche, R. O., Laine, L., Moskovitz, B. L., Mallegol, I., & Wu, J. (1997) · The Journal of Infectious Diseases · doi:10.1086/514028 · Cited by 108
Fungal Peritonitis in Patients on Peritoneal Dialysis
Michel, C., Courdavault, L., Khayat, R. A., Viron, B., Roux, P., & Mignon, F. (1994) · American Journal of Nephrology · doi:10.1159/000168699 · Cited by 107
Clemons, K. V., & Stevens, D. A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.899 · Cited by 105
Martins, M. D., Lozano‐Chiu, M., & Rex, J. H. (1998) · Clinical Infectious Diseases · doi:10.1086/515006 · Cited by 103 · cited 1×
“albicans and reduced frequency of symptomatic episodes of oropharyngeal candidiasis [156].”
BackgroundAzole resistance in Candida albicans
Smith, K. J., Warnock, D. W., Kennedy, C. T. C., Johnson, E. M., Hopwood, V., van Cutsem, J., & Vanden Bossche, H. (1986) · Medical Mycology · doi:10.1080/02681218680000201 · Cited by 103
Fungal infections of the heart: Analysis of 51 autopsy cases
Walsh, T. J., Hutchins, G. M., Bulkley, B. H., & Mendelsohn, G. (1980) · The American Journal of Cardiology · doi:10.1016/0002-9149(80)90659-1 · Cited by 101
Self-citationWalsh, T. J., Hiemenz, J., & Pizzo, P. A. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.5.793 · Cited by 100
Self-citationUse of Fluconazole in the Treatment of Candidal Endophthalmitis
Akler, M. E., Vellend, H., McNeely, D. M., Walmsley, S. L., & Gold, W. L. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.3.657 · Cited by 98
Miyazaki, M., Ito, H., & Nakagawa, K. (2000) · American Journal of Roentgenology · doi:10.2214/ajr.174.4.1741169 · Cited by 96
Pons, V., Greenspan, D., & Debruin, M. (1993) · PubMed · Cited by 93
STRINDEN, W. D., HELGERSON, R. B., & MAKI, D. G. (1985) · Annals of Surgery · doi:10.1097/00000658-198511000-00019 · Cited by 93
Leu, H.-S., & Huang, C.-T. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.5.1152 · Cited by 93 · cited 1×
“Bladder irrigation or wash with amphotericin B (50-200 mg/mL) may transiently clear funguria [80] but is rarely indicated (CIII) except as a diagnostic localizing tool [81].”
BackgroundEmpiric Therapy with Amphotericin B in Febrile Granulocytopenic Patients
Walsh, T. J., Lee, J., Lecciones, J., Rubin, M., Butler, K., Francis, P., Weinberger, M., Roilides, E., Marshall, D., Gress, J., et al. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.3.496 · Cited by 93
Self-citationYoon, S. A., Vazquez, J. A., Steffan, P. E., Sobel, J. D., & Akins, R. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.836 · Cited by 90
Self-citationCandida prosthetic arthritis: report of a case treated with fluconazole and review of the literature
Tunkel, A. R., Thomas, C. Y., & Wispelwey, B. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90127-b · Cited by 90
Pelletier, R., Peter, J., Antin, C., Gonzalez, C., Wood, L., & Walsh, T. J. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.4.1563-1568.2000 · Cited by 90
Self-citationActivity of terbinafine in experimental fungal infections of laboratory animals
Petranyi, G., Meingassner, J. G., & Mieth, H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.10.1558 · Cited by 89
Clancy, C. J., & Nguyen, M. H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1289 · Cited by 89
Hospital-associated Candiduria: Predisposing Factors and Review of The Literature
Hamory, B. H., & Wenzelt, R. P. (1978) · Journal of Urology · doi:10.1016/s0022-5347(17)57223-7 · Cited by 89
Phillips, P., Zemcov, J., Mahmood, W., Montaner, J. S. G., Craib, K., & Clarke, A. M. (1996) · AIDS · doi:10.1097/00002030-199610000-00009 · Cited by 88 · cited 1×
“Approximately 64% of patients with fluconazole-refractory infections will respond to itraconazole solution [140].”
BackgroundHIV-1 RNA levels and the development of clinical disease
Philips, A. N., Eron, J. J., Bartlett, J. A., Rubin, M., Johnson, J., Price, S., Self, P., & hill, A. M. (1996) · AIDS · doi:10.1097/00002030-199607000-00009 · Cited by 88
Martinez‐Vazquez, C., Fernandez‐Ulloa, J., Bordon, J., Sopena, B., la Fuente, J. D., Ocampo, A., & Rubianes, M. (1998) · Clinical Infectious Diseases · doi:10.1086/514972 · Cited by 88
Pfaller, M. A., Messer, S. A., & Hollis, R. J. (1994) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(94)90106-6 · Cited by 86 · cited 1×
“d Although frank amphotericin B resistance is not seen in all isolates, it is well described for isolates of this species [13, 14].”
BackgroundFungal Infections of the Genitourinary System
Wise, G. J., & Silver, D. A. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)36396-6 · Cited by 85 · cited 2×
“Urinary candidiasis includes an ill-defined group of syndromes [74].”
BackgroundSwenson, C. E., Perkins, W. R., Roberts, P., Ahmad, I., Stevens, R., Stevens, D. A., & Janoff, A. S. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.767 · Cited by 82
Fisher, M. A., Shen, S. H., Haddad, J., & Tarry, W. F. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1443 · Cited by 81
Vandewoude, K., Vogelaers, D., Decruyenaere, J., Jaqmin, P., De Beule, K., Van Peer, A., Woestenborghs, R., Groen, K., & Colardyn, F. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.12.2714 · Cited by 79
Barbaro, G., Barbarini, G., Calderon, W., Grisorio, B., Alcini, P., & Di Lorenzo, G. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8898629 · Cited by 78 · cited 1×
“Fluconazole is superior to ketoconazole, itraconazole capsules, and flucytosine for the treatment of esophageal candidiasis [146–148].”
BackgroundPractice Guidelines for the Treatment of Fungal Infections
Sobel, J. D., & Mycoses Study Group (2000) · Clinical Infectious Diseases · doi:10.1086/313746 · Cited by 77
Self-citationLevine, J. S., Bernard, D. B., Idelson, B. A., Farnham, H., Saunders, C., & Sugar, A. M. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90481-6 · Cited by 75
New approaches to the treatment of onychomycosis
Roseeuw, D. I., & Doncker, P. D. (1993) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(08)81837-3 · Cited by 75
Refractory Mucosal Candidiasis in Patients with Human Immunodeficiency Virus Infection
Fichtenbaum, C. J., & Powderly, W. G. (1998) · Clinical Infectious Diseases · doi:10.1086/514571 · Cited by 74
Chronic mucocutaneous candidiasis
Kirkpatrick, C. H. (1989) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01964059 · Cited by 73
Cm, W., Alexander, L., Clark, W. S., & Thompson, S. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8964406 · Cited by 73
Oral therapeutic agents in fungal nail disease
Roberts, D. T. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(08)81274-1 · Cited by 73
Fasano, C., O'Keeffe, J., & Gibbs, D. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01974619 · Cited by 72
Candida Epiglottitis in Immunocompromised Patients
Walsh, T. J., & Gray, W. C. (1987) · Chest · doi:10.1378/chest.91.4.482 · Cited by 71
Self-citationPhillips, P., De Beule, K., Frechette, G., Tchamouroff, S., Vandercam, B., Weitner, L., Hoepelman, A., Stingl, G., & Clotet, B. (1998) · Clinical Infectious Diseases · doi:10.1086/516342 · Cited by 71
Treatment Options for Vulvovaginal Candidiasis, 1993
Reef, S. E., Levine, W. C., McNeil, M. M., Fisher-Hoch, S., Holmberg, S. D., Duerr, A., Smith, D., Sobel, J. D., & Pinner, R. W. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.supplement_1.s80 · Cited by 70
Self-citationKörting, H. C., Schäfer‐Korting, M., Zienicke, H., Georgii, A., & Ollert, M. W. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.10.2064 · Cited by 67
Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Dib, O. P., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., Hilsenbeck, S. G., & Patterson, T. F. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00137-5 · Cited by 67
Candida tropicalis Vertebral Osteomyelitis: A Late Sequela of Fungemia
Ferra, C. M., Doebbeling, B. N., Hollis, R. J., Pfaller, M. A., Lee, C. K., & Gingrich, R. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.4.697 · Cited by 66
Sobel, J. D., & Vazquez, J. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.4.726 · Cited by 62
Self-citationHennequin, C., Bouree, P., Hiesse, C., Dupont, B., & Charpentier, B. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.1.176 · Cited by 61
Zhou, H., Goldman, M., Wu, J., Woestenborghs, R., Hassell, A. E., Lee, P., Baruch, A., Pesco‐Koplowitz, L., Borum, J., & Wheat, L. J. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04465.x · Cited by 60
Factors Associated with Fatal Hemoptysis in Cancer Patients
Panos, R. J., Barr, L. F., Walsh, T. J., & Silverman, H. J. (1988) · Chest · doi:10.1378/chest.94.5.1008 · Cited by 59
Self-citationFinlay, P. M., Richardson, M. D., & Robertson, A. G. (1996) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0266-4356(96)90130-8 · Cited by 59
Wilcox, C. M., Straub, R. F., & Clark, W. S. (1995) · PubMed · Cited by 59
Treatment of oral candidosis with itraconazole: A review
Blatchford, N. R. (1990) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(90)70256-h · Cited by 56
Fungal infections complicating orthotopic liver transplantation.
Karchmer, A. W., Samore, M. H., Hadley, S., Collins, L. A., Jenkins, R. L., & Lewis, W. D. (1995) · PubMed Central · Cited by 55
Fungal infections in iatrogenically compromised hosts.
Rex, J. H., Tj, W., & Ej, A. (1998) · PubMed · Cited by 54
Self-citationSeay, R. E., Larson, T. A., Toscano, J. P., Bostrom, B., O’Leary, M., & Uden, D. L. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb04331.x · Cited by 54
Candidal Mediastinitis: An Emerging Clinical Entity
Clancy, C. J., Nguyen, M. H., & Morris, A. J. (1997) · Clinical Infectious Diseases · doi:10.1086/513770 · Cited by 53 · cited 1×
“On the basis of a small number of cases, Candida mediastinitis may be treated with surgical debridement followed by either amphotericin B or fluconazole [96] (CIII).”
BackgroundSugar, A. M., Saunders, C., & Diamond, R. D. (1990) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(90)90084-9 · Cited by 53
Stewart, D., Guo, D., Morris, D. G., et al. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701536 · Cited by 53
Elewski, B. E. (1997) · Archives of Dermatology · doi:10.1001/archderm.1997.03890460143029 · Cited by 52
Late Recurrent Candida Endocarditis
Johnston, P. G., Lee, J., Domunski, M., Dressler, F., Tucker, E., Rothenberg, M., Cunnion, R. E., Pizzo, P. A., & Walsh, T. J. (1991) · Chest · doi:10.1378/chest.99.6.1531 · Cited by 51 · cited 1×
“Candida endocarditis has a propensity for relapse and requires careful follow-up for >1 year [113].”
BackgroundSelf-citationDoncker, P. D., Lint, J. V., Dockx, P., & Roseeuw, D. I. (1995) · PubMed · Cited by 50
Amphotericin B Colloidal Dispersion for Treatment of Candidemia in Immunocompromised Patients
Noskin, G. A., Pietrelli, L., Coffey, G., Gurwith, M., & Liang, L. (1998) · Clinical Infectious Diseases · doi:10.1086/516314 · Cited by 49
Seay, R. E., Larson, T. A., Toscano, J. P., Bostrom, B., O’Leary, M., & Uden, D. L. (1995) · PubMed · Cited by 48
Candida Pericarditis: Clinical Profile and Treatment
Rabinovici, R., Szewczyk, D., Ovadia, P., Greenspan, J. R., & Sivalingam, J. J. (1997) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(97)00086-6 · Cited by 48
Purulent Pericarditis Caused by Candida Species: Case Report and Review
Schrank, J. H., & Dooley, D. P. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.1.182 · Cited by 48
Antifungal agents in neonatal systemic candidiasis
van den Anker, J. N., van Popele, N. M., & Sauer, P. J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1391 · Cited by 46 · cited 2×
“In particular, the pharmacology of fluconazole varies with neonatal age, making rational dosing somewhat difficult [31, 35, 36].”
BackgroundEfficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole
Dewsnup, D. H., & Stevens, D. A. (1994) · Medical Mycology · doi:10.1080/02681219480000511 · Cited by 43
Candidal Suppurative Peripheral Thrombophlebitis Recognition, Prevention, and Management
Walsh, T. J., Bustamente, C. I., Vlahov, D., & Standiford, H. C. (1986) · Infection Control · doi:10.1017/s0195941700063736 · Cited by 43 · cited 1×
“Suppurative peripheral thrombophlebitis responds to surgical resection of the infected vein and antifungal therapy with amphotericin B or fluconazole [111].”
BackgroundSelf-citationSuccessful treatment of Candida albicans osteomyelitis with fluconazole
Tang, C. M. (1993) · Journal of Infection · doi:10.1016/0163-4453(93)97064-5 · Cited by 42
Eichel, M., Just‐Nübling, G., Helm, E. B., & Stille, W. (1996) · Mycoses · doi:10.1111/j.1439-0507.1996.tb00514.x · Cited by 41
Bárbaro, G., Barbarini, G., & Lorenzo, G. D. (1996) · CHEST Journal · doi:10.1378/chest.110.6.1507 · Cited by 40
Karyotakis, N. C., Anaissie, E. J., Hachem, R., Dignani, M. C., & Samonis, G. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/168.5.1311 · Cited by 40
Candida Endophthalmitis Complicating Candidemia
Meyers, B. R., LIEBERMAN, T. W., & FERRY, A. P. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-5-647 · Cited by 39
Vertebral Candida Infections: A Case Report and Review of the Literature
Almekinders, L. C., & Greene, W. B. (1991) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199106000-00027 · Cited by 38
Fluconazole prophylaxis for high-risk liver transplant recipients
Kung, N. N. S., Fisher, N. C., Gunson, B. K., Hastings, M., & Mutimer, D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92014-5 · Cited by 37
Fluconazole versus Amphotericin B in the Treatment of Esophageal Candidiasis in Cancer Patients
Lake, D. E. E., Kumweiler, J., Beer, M., Buell, D. N., & Islam, M. Z. (1996) · Chemotherapy · doi:10.1159/000239459 · Cited by 37
H, R. H. (1979) · Journal of The Royal Naval Medical Service · doi:10.1136/jrnms-65-176 · Cited by 37
Congenital Cutaneous Candidiasis
Kam, L. A. (1975) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1975.02120470059017 · Cited by 35
Martinez-Suarez, J. V., & Rodriguez-Tudela, J. L. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1512 · Cited by 34
Michallet, M., Persat, F., Kranzhöfer, N., Levron, J.-C., Prat, C., Belhabri, A., Chwetzoff, E., Le Moing, J.-P., Fiere, D., & Piens, M.-A. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701270 · Cited by 31 · cited 1×
“If used, initiation of therapy with the iv formulation is appropriate, as the bioavailability of the current oral formulations of itraconazole (including the cyclodextrin solution) is unpredictable [62, 63].”
BackgroundThe natural history of esophageal candidiasis after successful treatment in patients with AIDS
Laine, L. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90122-8 · Cited by 30
Meunier, F., Paesmans, M., & Autier, P. (1994) · European Journal of Cancer Part B Oral Oncology · doi:10.1016/0964-1955(94)90091-4 · Cited by 29
Fluconazole Suspension for Oropharyngeal Candidiasis Unresponsive to Tablets
Martins, M. D., & Rex, J. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-4-199702150-00020 · Cited by 28
Self-citationManagement of Septic Thrombosis of the Inferior Vena Cava Caused by Candida
Jarrett, F. (1978) · Archives of Surgery · doi:10.1001/archsurg.1978.01370170099020 · Cited by 28
Barbaro, G., Barbarini, G., & Di Lorenzo, G. (1995) · Endoscopy · doi:10.1055/s-2007-1005717 · Cited by 27
Weers-Pothoff, G., Havermans, J. F., Kamphuis, J., Sinnige, H. A. M., & Meis, J. F. G. M. (1997) · Infection · doi:10.1007/bf02113588 · Cited by 27 · cited 1×
“Adequate and/or repeated drainage is often critical to successful therapy [94].”
BackgroundLong-Term Suppressive Therapy for Candida parapsilosis-Induced Prosthetic Valve Endocarditis
Baddour, L. M. (1995) · Mayo Clinic Proceedings · doi:10.4065/70.8.773 · Cited by 27
Amphotericin B in the treatment of Candida cholecystitis
ADAMSON, P. C., RINALDI, M. G., PIZZO, P. A., & WALSH, T. J. (1989) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-198906000-00030 · Cited by 25
Self-citationFong, I. W., Cheng, P.-S., & HINTON, N. A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.9.1856 · Cited by 24
Use of itraconazole in a patient with chronic mucocutaneous candidiasis
Burke, W. A. (1989) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(89)80315-9 · Cited by 23
Pfaller, M. A., Bale, M. J., Buschelman, B. J., & Rhomberg, P. R. (1994) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(94)90116-3 · Cited by 22
Marr, B., Groß, S., Cunningham, C. K., & Weiner, L. B. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.4.795 · Cited by 22
Agresti, M. G., Bernardis, F. D., Mondello, F., Bellocco, R., Carosi, G., Caputo, R., Milazzo, F., Chiodo, F., Giannini, V., Minoli, L., et al. (1994) · European Journal of Epidemiology · doi:10.1007/bf01717446 · Cited by 20
Laryngeal candidiasis: A cause of airway obstruction in the immunocompromised child
Fisher, E. W., Richards, A., Anderson, G., & Albert, D. M. (1992) · The Journal of Laryngology & Otology · doi:10.1017/s0022215100118997 · Cited by 19
Candida Endocarditis and Amphotericin B Intolerance: Potential Role for Fluconazole
Castiglia, M., Smego, R. A., & Sames, E. L. (1994) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-199407000-00004 · Cited by 14
Laryngeal Candidiasis in Children
Wang, J.-N., Liu, C.-C., Huang, T.-Z., Huang, S.-S., & Wu, J.-M. (1997) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549709011846 · Cited by 12
Boogaerts, M., Garber, G. E., Winston, D. J., et al. (1999) · Bone Marrow Transplantation · Cited by 12
Treatment of Thrush with Itraconazole Solution: Evidence for Topical Effect
Mascareñas, C. A., Hardin, T. C., Pennick, G. J., Rinaldi, M. G., & Graybill, J. R. (1998) · Clinical Infectious Diseases · doi:10.1086/598361 · Cited by 10
Association of Candida with carcinoma of esophagus.
Bhatia, V., Kochhar, R. K., Talwar, P., Gupta, N., & Mehta, S. K. (1989) · PubMed · Cited by 10
MEDICAL MANAGEMENT OF FUNGAL SUPPURATIVE THROMBOSIS OF GREAT CENTRAL VEINS IN A CHILD
Berg, R. A., & Stein, J. M. (1989) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-198907000-00011 · Cited by 7
Walsh (1995) · doi:10.1002/1097-0142(19951201)76:11
Research works printed but not linked: 26
- -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/177.2.425 · doi:10.1093/jnlids/177.2.425
- 1998, Clinical Infectious Diseases, 27, 981
- -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/168.5.1311 · doi:10.1093/jnlids/168.5.1311
- 1998, Clinical Infectious Diseases, 27, 938
- 1999, Antimicrobial Agents and Chemotherapy, 43, 1289, 10.1128/AAC.43.5.1289 · DOI · Paper page
- -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/173.5.1208 · doi:10.1093/jnlids/173.5.1208
- 1998, Medical mycology : official publication of the International Society for Human and Animal Mycology, 36, 156
- THALER, 1988, Annals of Internal Medicine, 108, 88, 10.1059/0003-4819-108-1-88 · doi:10.1059/0003-4819-108-1-88
- 1995, 76, 2357, 10.1002/1097-0142(19951201)76:11<2357::AID-CNCR2820761126>3.0.CO;2-H · doi:10.1002/1097-0142(19951201)76:11<2357::aid-cncr2820761126>3.0.co;2-h
- 1991, Clinical orthopaedics and related research, 267, 174
- Solomkin, 1980, Surgery, 88, 524
- MEYERS, 1973, Annals of Internal Medicine, 79, 647, 10.1059/0003-4819-79-5-647 · doi:10.1059/0003-4819-79-5-647
- Pons, 1993, Journal of acquired immune deficiency syndromes, 6, 1311
- Bonacini, 1991, Archives of Internal Medicine, 151, 1567, 10.1001/archinte.1991.00400080067012 · doi:10.1001/archinte.1991.00400080067012 · Paper page
- Bhatia, 1989, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 8, 171
- 1996, 110, 1803
- Laine, 1992, Annals of Internal Medicine, 117, 655, 10.1059/0003-4819-117-8-655 · doi:10.1059/0003-4819-117-8-655
- 1996, 111, 1169
- -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/176.1.227 · doi:10.1093/jnlids/176.1.227
- 1994, 107, 744
- De Doncker, 1995, Cutis; cutaneous medicine for the practitioner, 56, 180
- -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/171.6.1545 · doi:10.1093/jnlids/171.6.1545
- 1994, Transactions of the American Clinical and Climatological Association, 106, 38
- -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/170.3.644 · doi:10.1093/jnlids/170.3.644
- 1995, Lancet, 349, 1234
- Benedetti, 1996, Journal of the American College of Surgeons, 183, 307
Cited by
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Guidelines for the management of intravascular catheter-related infections
Mermel, L. A., Farr, B. M., Sherertz, R. J., Raad, I. I., O'Grady, N., Harris, J. S., & Craven, D. E. (2001) · Clinical Infectious Diseases · doi:10.1086/320001 · Cited by 1,449
Infective Endocarditis in Adults
Mylonakis, E., & Calderwood, S. B. (2001) · New England Journal of Medicine · doi:10.1056/nejmra010082 · Cited by 1,324
Sardi, J. C. O., Scorzoni, L., Bernardi, T., Fusco-Almeida, A. M., & Mendes Giannini, M. J. S. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.045054-0 · Cited by 1,184
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Metadata
- Authors
- Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E.
- Affiliations
- Texas Medical Center (US)
- National Cancer Institute (US)
- Wayne State University (US)
- Harbor–UCLA Medical Center (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Rex, J. H.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-04-01
- Volume
- 30
- Issue
- 4
- Pages
- 662-678
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2143449612
- Cited by
- 927
- References
- 185
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 8 · 2022: 12 · 2021: 12 · 2020: 10 · 2019: 14 · 2018: 13 · 2017: 15 · 2016: 12 · 2015: 13 · 2014: 24 · 2013: 20 · 2012: 47
- FWCI
- 66.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- candidiasis, Candida, invasive candidiasis, mucocutaneous candidiasis, oropharyngeal candidiasis, vaginal candidiasis, candidiasis treatment, antifungal agents, amphotericin B, azole antifungals, 5-fluorocytosine, antifungal susceptibility testing, non-albicans Candida, Candida krusei, relapse, neutropenia, HIV infection, treatment guidelines, interpretive breakpoints
- MeSH terms
- Adult, Amphotericin B, Antifungal Agents, Candida, Candidiasis, Child, Child, Preschool, Cost-Benefit Analysis, Female, Fever, Humans, Microbial Sensitivity Tests, Neutropenia, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.